Acadia shed $3.96 (15%) to $22.01 in after hours trading Monday when it reported after market close that Nuplazid pimavanserin as an adjunct schizophrenia therapy missed the primary endpoint and key secondary endpoint in the Phase III ENHANCE trial.
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2024,